Alpha Wave Global LP Acquires Shares of 2,384,050 Metsera Inc. $MTSR

Key Points

• Alpha Wave Global LP acquired 2,384,050 shares of Metsera Inc. ($MTSR) in Q1, making it the investor's 2nd largest position at approximately $64.9 million.
• Several other institutional investors, including Alphabet Inc. and T. Rowe Price, also purchased significant stakes in Metsera during the same period, reflecting growing interest in the company.
• Metsera’s stock price has shown volatility with a 12-month low of $12.30 and a high of $47.40, and it currently has an average analyst rating of "Buy".

Alpha Wave Global LP bought a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,384,050 shares of the company's stock, valued at approximately $64,894,000. Metsera makes up approximately 28.9% of Alpha Wave Global LP's portfolio, making the stock its 2nd biggest position. Alpha Wave Global LP owned approximately 2.27% of Metsera as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Alphabet Inc. bought a new position in shares of Metsera during the first quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. bought a new position in shares of Metsera during the first quarter valued at approximately $78,748,000. Wellington Management Group LLP bought a new position in shares of Metsera during the first quarter valued at approximately $65,382,000. Price T Rowe Associates Inc. MD bought a new position in shares of Metsera during the first quarter valued at approximately $42,395,000. Finally, Vanguard Group Inc. bought a new position in shares of Metsera during the first quarter valued at approximately $39,932,000.

Metsera Price Performance

NASDAQ MTSR opened at $32.59 on Tuesday. Metsera Inc. has a 12 month low of $12.30 and a 12 month high of $47.40. The stock's fifty day moving average price is $33.42 and its 200-day moving average price is $28.36.

Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MTSR. Guggenheim upped their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Wells Fargo & Company began coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $55.00.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Want to see what other hedge funds are holding MTSR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metsera Inc. (NASDAQ:MTSR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.